You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ECCCHO: Effective Combat Casualty Care Handoff Operations

    SBC: TIER 1 PERFORMANCE SOLUTIONS LLC            Topic: DHA17B002

    Approximately 70% of sentinel events in medical care are related to communication mishaps, and despite regular and frequent occurrence, an even higher percentage (80%) of severe medical errors are related to miscommunication during handoffs (i.e., the transferring of information, responsibility, and authority for patient care from one provider to another). The TiER1 team proposes to address challe ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  2. Commercialization of a Rapid Blood Test for Traumatic Brain Injury

    SBC: Fawkes Biotechnology, LLC            Topic: 100

    Traumatic brain injuryTBIis a substantial health care issue affecting both civilian and military populationsAlthough extremes of head injury are recognizablemild to moderate TBImmTBIis more difficult to diagnose leading to a need for the identification of circulating biomarkers of brain injury that may facilitate early identificationUsing a rat model of TBI we identified a novel marker of neuronal ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A universal eye drop adherence monitor to measure and improve adherence to ocular medications

    SBC: Universal Adherence LLC            Topic: N

    Project Summary Abstract Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutionsOur proposed Devers Drop DeviceDwill accurately track when a patient removes an eye drop bottle capcommunicate usage data wirelessly to a database that researchers can accessand send alerts to patients when a medication is d ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Numeric Expansion of CD-19 Specific T cells in Magnetic 3D Culture

    SBC: CHEMOSEN3D INC            Topic: NIAID

    Project Summary Adoptive immunotherapy trials using genetically modified natural killerNKand T cells with redirected specificity against B cell malignancies have demonstrated therapeutic efficacyTwo early phase clinical trials have been initiated at The University of Texas MDAnderson Cancer Center to evaluate the safety and efficacy of adoptive transfer of autologous and allogeneic T cells express ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Small molecule Inhibitors of steroid receptor coactivator to treat breast cancer

    SBC: Coactigon, Inc.            Topic: 102

    ABSTRACTSteroid Receptor CoactivatorSRCis a key breast cancer oncogene that is frequently overexpressed or amplified in estrogen receptorERand human epidermal growth factor receptorHERpositive breast cancersElevated expression of SRCalso has been associated with resistance to tamoxifen therapy and with poor disease outcome in HERpositive breast cancersNumerous studies have shown that experimental ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's Disease

    SBC: Amprion, Inc.            Topic: NIA

    ABSTRACT This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a test for high sensitive detection of tau oligomers in biological fluidswhich could be used for the biochemical diagnosis of Alzheimerandapos s diseaseADand related tauopathiesAD is the most common dementia in the elderly population and one of the leading causes of death in the develop ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)

    SBC: NANOHYBRIDS INC            Topic: N

    ABSTRACTThe wet form of age related macular degenerationAMDaccounts forof all AMD related blindness and affectsmillion people withnew cases each year in the USMinimally invasive and selective drug delivery to the eye still remains an open challengethe current standard of care involves delivery of antivascular endothelial growth factoranti VEGFdrugs via intraocular injectionFor patients refractory ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. In Silico Identification of Novel GHB Receptor Ligands for SSADH Deficiency, a Disorder of GABA Metabolism

    SBC: SPERAGEN, INC.            Topic: 102

    Summary The most prevalent inherited disorder of GABA metabolismsuccinic semialdehyde dehydrogenase deficiencySSADHDpresents a non specific neurological phenotype associated with physiological accumulation of the major inhibitory neurotransmitter GABA and the GABAderivativehydroxybutyrateGHBAn absence of targeted therapy for SSADHD underlies this application s rationalePreclinical and clinical stu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government